

FOR RELEASE December 15, 2011

Contacts: Rob Stewart Investor Relations Tel (949) 480-8300 Fax (949) 480-8301 Media Contact: Adam Handelsman Managing Director Lippert/Heilshorn & Associates (212) 201-6622 ahandelsman@lhai.com

ACACIA SUBSIDIARY ENTERS INTO SETTLEMENT AGREEMENT WITH SRU BIOSYSTEMS, INC.

Newport Beach, Calif. – (BUSINESS WIRE) December 15, 2011 – Acacia Research Corporation (Nasdaq: ACTG) announced today that its subsidiary, Resonant Biotechnologies LLC, has entered into a settlement agreement with SRU Biosystems, Inc. This agreement resolves patent litigation that was pending in the United States District Court for the District of New Jersey.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation's subsidiaries partner with inventors and patent owners, license the patents to corporate users, and share the revenue. Acacia Research Corporation's subsidiaries control over 200 patent portfolios, covering technologies used in a wide variety of industries.

Information about Acacia Research Corporation and its subsidiaries is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting

technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.